Biologic response modifiers for granulomatosis with polyangiitis (Wegener's)

From promise to reality

Jeremy M. Clain, Rodrigo Cartin-Ceba, Ulrich Specks

Research output: Contribution to journalArticle

Abstract

Advances in the treatment of granulomatosis with polyangiitis (GPA; formerly Wegener's granulomatosis) have resulted in marked improvements in patient outcomes. While severe GPA was originally described as progressive and invariably fatal, the use of immunosuppressive therapy has transformed the disease into a manageable, chronically relapsing illness. However, standard immunosuppressive therapies are associated with numerous side effects and significant treatment failures. In an effort to provide safer and more effective treatments for patients with GPA, several alternative therapies have been investigated in recent years, most notably among biologic response modifiers. The use of biologic response modifiers in GPA has had mixed results. The efficacy of rituximab in GPA is now firmly established, while inhibitors of TNF-α have not shown clear benefits. Investigations into other biologic response modifiers in GPA remain preliminary, but hold promise for a future in which the treatment of GPA achieves further improvements in outcomes with fewer side effects.

Original languageEnglish (US)
Pages (from-to)383-397
Number of pages15
JournalInternational Journal of Clinical Rheumatology
Volume8
Issue number3
DOIs
StatePublished - Jun 2013

Fingerprint

Granulomatosis with Polyangiitis
Immunosuppressive Agents
Therapeutics
Complementary Therapies
Treatment Failure

Keywords

  • alemtuzumab
  • ANCA-associated vasculitis
  • B-cell activating factor
  • biologic response modifiers
  • CTLA-4 antigen
  • granulomatosis with polyangiitis
  • rituximab
  • TNF-α
  • Wegener's granulomatosis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Biologic response modifiers for granulomatosis with polyangiitis (Wegener's) : From promise to reality. / Clain, Jeremy M.; Cartin-Ceba, Rodrigo; Specks, Ulrich.

In: International Journal of Clinical Rheumatology, Vol. 8, No. 3, 06.2013, p. 383-397.

Research output: Contribution to journalArticle

@article{5338ad1a18854424b85f71be9bbb1ddb,
title = "Biologic response modifiers for granulomatosis with polyangiitis (Wegener's): From promise to reality",
abstract = "Advances in the treatment of granulomatosis with polyangiitis (GPA; formerly Wegener's granulomatosis) have resulted in marked improvements in patient outcomes. While severe GPA was originally described as progressive and invariably fatal, the use of immunosuppressive therapy has transformed the disease into a manageable, chronically relapsing illness. However, standard immunosuppressive therapies are associated with numerous side effects and significant treatment failures. In an effort to provide safer and more effective treatments for patients with GPA, several alternative therapies have been investigated in recent years, most notably among biologic response modifiers. The use of biologic response modifiers in GPA has had mixed results. The efficacy of rituximab in GPA is now firmly established, while inhibitors of TNF-α have not shown clear benefits. Investigations into other biologic response modifiers in GPA remain preliminary, but hold promise for a future in which the treatment of GPA achieves further improvements in outcomes with fewer side effects.",
keywords = "alemtuzumab, ANCA-associated vasculitis, B-cell activating factor, biologic response modifiers, CTLA-4 antigen, granulomatosis with polyangiitis, rituximab, TNF-α, Wegener's granulomatosis",
author = "Clain, {Jeremy M.} and Rodrigo Cartin-Ceba and Ulrich Specks",
year = "2013",
month = "6",
doi = "10.2217/ijr.13.23",
language = "English (US)",
volume = "8",
pages = "383--397",
journal = "Future Rheumatology",
issn = "1758-4272",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Biologic response modifiers for granulomatosis with polyangiitis (Wegener's)

T2 - From promise to reality

AU - Clain, Jeremy M.

AU - Cartin-Ceba, Rodrigo

AU - Specks, Ulrich

PY - 2013/6

Y1 - 2013/6

N2 - Advances in the treatment of granulomatosis with polyangiitis (GPA; formerly Wegener's granulomatosis) have resulted in marked improvements in patient outcomes. While severe GPA was originally described as progressive and invariably fatal, the use of immunosuppressive therapy has transformed the disease into a manageable, chronically relapsing illness. However, standard immunosuppressive therapies are associated with numerous side effects and significant treatment failures. In an effort to provide safer and more effective treatments for patients with GPA, several alternative therapies have been investigated in recent years, most notably among biologic response modifiers. The use of biologic response modifiers in GPA has had mixed results. The efficacy of rituximab in GPA is now firmly established, while inhibitors of TNF-α have not shown clear benefits. Investigations into other biologic response modifiers in GPA remain preliminary, but hold promise for a future in which the treatment of GPA achieves further improvements in outcomes with fewer side effects.

AB - Advances in the treatment of granulomatosis with polyangiitis (GPA; formerly Wegener's granulomatosis) have resulted in marked improvements in patient outcomes. While severe GPA was originally described as progressive and invariably fatal, the use of immunosuppressive therapy has transformed the disease into a manageable, chronically relapsing illness. However, standard immunosuppressive therapies are associated with numerous side effects and significant treatment failures. In an effort to provide safer and more effective treatments for patients with GPA, several alternative therapies have been investigated in recent years, most notably among biologic response modifiers. The use of biologic response modifiers in GPA has had mixed results. The efficacy of rituximab in GPA is now firmly established, while inhibitors of TNF-α have not shown clear benefits. Investigations into other biologic response modifiers in GPA remain preliminary, but hold promise for a future in which the treatment of GPA achieves further improvements in outcomes with fewer side effects.

KW - alemtuzumab

KW - ANCA-associated vasculitis

KW - B-cell activating factor

KW - biologic response modifiers

KW - CTLA-4 antigen

KW - granulomatosis with polyangiitis

KW - rituximab

KW - TNF-α

KW - Wegener's granulomatosis

UR - http://www.scopus.com/inward/record.url?scp=84879618818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879618818&partnerID=8YFLogxK

U2 - 10.2217/ijr.13.23

DO - 10.2217/ijr.13.23

M3 - Article

VL - 8

SP - 383

EP - 397

JO - Future Rheumatology

JF - Future Rheumatology

SN - 1758-4272

IS - 3

ER -